Am J Transplant, Volume 19, Suppl 3 Archives - Page 27 of 214 - ATC Abstracts

2019 American Transplant Congress
Whole-Exome Sequencing Identifies PMS1 and DYRK1A Genes Contributing to Occurrence of Liver Cancer
Y. Zhao, B. Yang, D. Chen, L. Wei, Z. Chen
Tongji hospital, Huazhong university, Organ Transplantation, Wuhan, China
*Purpose: Liver cancer is one of the most frequent cancers in China and the accurate landscape of liver cancer, especially of HBV-infected liver cancer in…
2019 American Transplant Congress
Impact of IgG Subclass and C1q Binding Donor-Specific HLA Antibodies on Antibody Mediated Rejection in Kidney Transplant Recipients
H. Lee¹, J. Ryu¹, S. Yun¹, T. Ban², E. Ko², C. Yang², E. Oh¹
¹Department of Laboratory Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ²Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea, Republic of
*Purpose: Donor specific HLA antibody (DSA) is a leading cause of antibody mediated rejection (AMR) and graft loss in kidney transplants. It is known that…
2019 American Transplant Congress
Novel Flow-Based Assay to Identify Allo-Specific T Cell Exhaustion
N. Tanimine¹, C. Rickert¹, K. Lee¹, K. Deng¹, N. Feeney¹, C. Leguern¹, B. Burrell², J. Markmann¹
¹Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Immune Tolerance Network, Bethesda, MD
*Purpose: A recent, multi-center immunosuppression withdrawal trial in liver transplant recipients unexpectedly revealed time post-transplant as an important predictor for operational tolerance. We hypothesize that…
2019 American Transplant Congress
Lack of Response to Tocilizumab in Kidney Transplants with Chronic Antibody-Mediated Rejection
D. Kumar¹, F. Safavi¹, R. Sandhu¹, P. Halloran², I. Yakubu¹, M. Levy¹, I. Moinuddin¹, P. Kimball¹, L. Kamal¹, A. King¹, H. Massey¹, G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada
*Purpose: Chronic antibody mediated rejection (cAbMR) is a major cause of long-term kidney transplant (KT) loss. Traditional therapies for cAbMR have unclear efficacy with significant…
2019 American Transplant Congress
The Impact of Eplet Mismatches on Kidney Transplant Outcome: A Single-Center Cohort Study
A. Senev¹, M. Coemans¹, V. Van Sandt², B. Sprangers³, D. Kuypers³, M. Emonds², M. Naesens³
¹Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, ²Histocompatibility and Immunogenetics Laboratory, Belgian Red Cross-Flanders, Mechelen, Belgium, ³University Hospitals Leuven, Leuven, Belgium
*Purpose: It has been shown that HLA-matching at classic antigen-level for HLA-A, -B and -DRB1 loci, provides benefits in matching and outcome after solid organ…
2019 American Transplant Congress
Renal Transplantation in Patients Older Than 60 Years with High Comorbidity. Is There a Survival Benefit? A Multicenter Study in Argentina
G. D. Fragale¹, G. A. Laham², L. Bisignano³, A. Antik³, P. M. Raffaele⁴, M. Fortunato⁴, H. Trimarchi⁵, V. Pomeranz⁵, R. Maldonado⁶, N. Matamala⁶, N. C. Imperiali⁷, M. C. Giordani⁷, M. F. Taylor⁸, J. M. Ciappa⁸, J. L. De La Fuente⁹, S. Naser¹⁰, G. Soler Pujol²
¹Nephrology, Hospital Universitario Austral, Derqui, Argentina, ²Nephrology, CEMIC, Buenos Aires, Argentina, ³INCUCAI, Buenos Aires, Argentina, ⁴Fundacion Favaloro, Buenos Aires, Argentina, ⁵Hospital Britanico de Buenos Aires, Buenos Aires, Argentina, ⁶Clinica Velez Sarsfield, Cordoba, Argentina, ⁷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Crai Sur, Buenos Aires, Argentina, ⁹Hospital Privado Universitario de Cordoba, Cordoba, Argentina, ¹⁰Hospital Privado Universitario de Cordoba, Buenos Aires, Argentina
*Purpose: The impact of renal transplantation (RT) in the elderly with comorbid conditions is a matter of concern. Our aim was to assess the impact…
2019 American Transplant Congress
Time within Therapeutic Range: A Comparison of Three Tacrolimus Formulations within Ninety Days of Renal Transplant
S. Patel, K. Khalil, A. Lichvar, E. Benedetti, P. West-Thielke
University of Illinois Hospital and Health Sciences System, Chicago, IL
*Purpose: Optimizing tacrolimus (TAC) time within therapeutic range (TTR) has been shown to improve outcomes post-transplant. To date, there are no studies assessing differences in…
2019 American Transplant Congress
Belatacept Use in High Kidney Donor Profile Index Kidney Transplant Recipients
D. Britt¹, A. Gharabagi¹, K. Botkin¹, T. Horwedel², C. Carthon¹, J. Hagopian¹
¹Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ²Veloxis Pharmaceuticals, Cary, NC
*Purpose: To determine whether the use of belatacept is associated with renal function preservation in kidney transplant recipients from donors with a kidney donor profile…
2019 American Transplant Congress
Impact of HLA-DR Matching on HLA-DQ Matching Status and the Development of Anti-HLA-DQ De Novo DSA under Calcineurin Inhibitor or Belatacept Immunosuppression
V. Jucaud¹, H. Gebel², R. Bray², M. Polinsky³, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Emory University, Atlanta, GA, ³Bristol-Myers Squibb, Princeton, NJ
*Purpose: De novo donor-specific HLA antibodies (dnDSA) that develop after kidney transplantation target more frequently allo-HLA-DQ antigens in comparison to other allo-HLA antigens. Yet, organ…
2019 American Transplant Congress
Combined Liver and Delayed Kidney Transplantation (CLKT) Enables Similar Patient Survival as Liver Transplantation Alone (LTA): Propensity Score-Based Comparison
B. Ekser¹, C. A. Kubal¹, R. S. Mangus¹, P. Mihaylov¹, J. A. Fridell¹, L. R. Timsina¹, M. Lacerda², M. Ghabril², J. A. Powelson¹, W. C. Goggins¹
¹Transplant Division - Department of Surgery - Indiana University, Indianapolis, IN, ²Gastroenterology, Indiana University, Indianapolis, IN
*Purpose: We previously showed the positive impact of delayed KT in CLKT on patient survival compared to simultaneous KT. It is well known from the…